Lenz Therapeutics announced a significant strategic reorganization, resulting in a 75% reduction of its workforce. This move comes as the company reported a third-quarter loss exceeding expectations and a substantial decline in its stock value. The CEO will also be transitioning out of his role in early December. These changes are intended to reduce operating expenses by 50% in 2027, with a majority of funds dedicated to a consumer-driven sales and marketing strategy. The company expects the restructuring to conclude by year-end.
San Francisco, California
https://www.fiercepharma.com/pharma/lenz-reports-75-workforce-cut-and-ceo-shakeup-q3-update